{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:06:13Z","timestamp":1792785973911,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"BridgeBio\/QED Therapeutics"},{"name":"National Research Agency","award":["ANR-10-IAHU-01"],"award-info":[{"award-number":["ANR-10-IAHU-01"]}]},{"DOI":"10.13039\/501100001961","name":"AXA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001961","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Philanthropy Department of Mutuelles AXA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Achondroplasia (ACH), the most common form of disproportionate short stature, is caused by gain\u2013of\u2013function point mutations in fibroblast growth factor receptor 3 (FGFR3). Abnormally elevated activation of FGFR3 modulates chondrocyte proliferation and differentiation via multiple signaling pathways, such as the MAPK pathway. Using a mouse model mimicking ACH (Fgfr3Y367C\/+), we have previously shown that daily treatment with infigratinib (BGJ398), a selective and orally bioavailable FGFR1-3 inhibitor, at a dose of 2\u00a0mg\/kg, significantly increased bone growth. In this study, we investigated the activity of infigratinib administered at substantially lower doses (0.2 and 0.5\u00a0mg\/kg, given once daily) and using an intermittent dosing regimen (1\u00a0mg\/kg every 3\u00a0days). Following a 15\u2013day treatment period, these low dosages were sufficient to observe significant improvement of clinical hallmarks of ACH such as growth of the axial and appendicular skeleton and skull development. Immunohistological labeling demonstrated the positive impact of infigratinib on chondrocyte differentiation in the cartilage growth plate and the cartilage end plate of the vertebrae. Macroscopic and microcomputed analyses showed enlargement of the foramen magnum area at the skull base, thus improving foramen magnum stenosis, a well\u2013recognized complication in ACH. No changes in FGF23 or phosphorus levels were observed, indicating that the treatment did not modify phosphate homeostasis. This proof\u2013of\u2013concept study demonstrates that infigratinib administered at low doses has the potential to be a safe and effective therapeutic option for children with ACH.<\/jats:p>","DOI":"10.1093\/jbmr\/zjae051","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T12:34:24Z","timestamp":1712234064000},"page":"765-774","source":"Crossref","is-referenced-by-count":14,"title":["Low\u2013dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model"],"prefix":"10.1093","volume":"39","author":[{"given":"Benoit","family":"Demuynck","sequence":"first","affiliation":[{"name":"Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia , INSERM UMR1163, , Paris , France"},{"name":"Universit\u00e9 de Paris Cit\u00e9, Imagine Institute , INSERM UMR1163, , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Flipo","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia , INSERM UMR1163, , Paris , France"},{"name":"Universit\u00e9 de Paris Cit\u00e9, Imagine Institute , INSERM UMR1163, , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Kaci","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia , INSERM UMR1163, , Paris , France"},{"name":"Universit\u00e9 de Paris Cit\u00e9, Imagine Institute , INSERM UMR1163, , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Dambkowski","sequence":"additional","affiliation":[{"name":"QED Therapeutics , San Francisco, CA 94107 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Paull","sequence":"additional","affiliation":[{"name":"QED Therapeutics , San Francisco, CA 94107 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Muslimova","sequence":"additional","affiliation":[{"name":"QED Therapeutics , San Francisco, CA 94107 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavik P","family":"Shah","sequence":"additional","affiliation":[{"name":"QED Therapeutics , San Francisco, CA 94107 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4989-5856","authenticated-orcid":false,"given":"Laurence","family":"Legeai-Mallet","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia , INSERM UMR1163, , Paris , France"},{"name":"Universit\u00e9 de Paris Cit\u00e9, Imagine Institute , INSERM UMR1163, , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"issue":"6","key":"2024072411420702300_ref1","doi-asserted-by":"crossref","first-page":"a015958","DOI":"10.1101\/cshperspect.a015958","article-title":"Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology","volume":"5","author":"Belov","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"2024072411420702300_ref2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"issue":"1","key":"2024072411420702300_ref3","doi-asserted-by":"crossref","first-page":"14003","DOI":"10.1038\/boneres.2014.3","article-title":"Role of FGF\/FGFR signaling in skeletal development and homeostasis: learning from mouse models","volume":"2","author":"Su","year":"2014","journal-title":"Bone Res"},{"issue":"14","key":"2024072411420702300_ref4","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1101\/gad.266551.115","article-title":"Fibroblast growth factor signaling in skeletal development and disease","volume":"29","author":"Ornitz","year":"2015","journal-title":"Genes Dev"},{"issue":"6","key":"2024072411420702300_ref5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/03008207.2015.1051224","article-title":"FGFR3 biology and skeletal disease","volume":"56","author":"Narayana","year":"2015","journal-title":"Connect Tissue Res"},{"issue":"1","key":"2024072411420702300_ref6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.berh.2007.12.008","article-title":"Achondroplasia","volume":"22","author":"Baujat","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9582","key":"2024072411420702300_ref7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0140-6736(07)61090-3","article-title":"Achondroplasia","volume":"370","author":"Horton","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"2024072411420702300_ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0972-6","article-title":"Achondroplasia: a comprehensive clinical review","volume":"14","author":"Pauli","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2024072411420702300_ref9","doi-asserted-by":"crossref","first-page":"115872","DOI":"10.1016\/j.bone.2021.115872","article-title":"Lifetime impact of achondroplasia: current evidence and perspectives on the natural history","volume":"146","author":"Hoover-Fong","year":"2021","journal-title":"Bone"},{"issue":"2","key":"2024072411420702300_ref10","first-page":"368","article-title":"Achondroplasia is defined by recurrent G380R mutations of FGFR3","volume":"56","author":"Bellus","year":"1995","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2024072411420702300_ref11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajhg.2011.12.017","article-title":"Paternal age effect mutations and selfish spermatogonial selection: causes and consequences for human disease","volume":"90","author":"Goriely","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"21","key":"2024072411420702300_ref12","doi-asserted-by":"crossref","first-page":"13007","DOI":"10.1074\/jbc.273.21.13007","article-title":"Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia","volume":"273","author":"Legeai-Mallet","year":"1998","journal-title":"J Biol Chem"},{"issue":"39","key":"2024072411420702300_ref13","doi-asserted-by":"crossref","first-page":"30103","DOI":"10.1074\/jbc.M109.094086","article-title":"Physical basis behind achondroplasia, the most common form of human dwarfism","volume":"285","author":"He","year":"2010","journal-title":"J Biol Chem"},{"issue":"2","key":"2024072411420702300_ref14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1128\/MCB.20.2.516-522.2000","article-title":"The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation","volume":"20","author":"Monsonego-Ornan","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2024072411420702300_ref15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ng0696-233","article-title":"Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia","volume":"13","author":"Naski","year":"1996","journal-title":"Nat Genet"},{"issue":"2","key":"2024072411420702300_ref16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11914-017-0347-2","article-title":"Current care and investigational therapies in achondroplasia","volume":"15","author":"Unger","year":"2017","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"2024072411420702300_ref17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/ajcn\/88.2.364","article-title":"Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height","volume":"88","author":"Hoover-Fong","year":"2008","journal-title":"Am J Clin Nutr"},{"issue":"20","key":"2024072411420702300_ref18","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J Med Chem"},{"issue":"5","key":"2024072411420702300_ref19","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI83926","article-title":"Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model","volume":"126","author":"Komla-Ebri","year":"2016","journal-title":"J Clin Invest"},{"issue":"2","key":"2024072411420702300_ref20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbadis.2008.11.010","article-title":"Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia","volume":"1792","author":"Pannier","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"2024072411420702300_ref21","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bone.2010.07.020","article-title":"Delayed bone age due to a dual effect of FGFR3 mutation in achondroplasia","volume":"47","author":"Pannier","year":"2010","journal-title":"Bone"},{"issue":"5","key":"2024072411420702300_ref22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neuchi.2019.09.010","article-title":"Animal models of craniosynostosis","volume":"65","author":"Cornille","year":"2019","journal-title":"Neurochirurgie"},{"issue":"11","key":"2024072411420702300_ref23","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1093\/hmg\/ddu004","article-title":"FGFR3 mutation causes abnormal membranous ossification in achondroplasia","volume":"23","author":"Di Rocco","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"14","key":"2024072411420702300_ref24","first-page":"2997","article-title":"Meckel's and condylar cartilages anomalies in achondroplasia result in defective development and growth of the mandible","volume":"25","author":"Biosse Duplan","year":"2016","journal-title":"Hum Mol Genet"},{"key":"2024072411420702300_ref25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000439334","article-title":"C-type natriuretic peptide analog as therapy for achondroplasia","volume":"30","author":"Legeai-Mallet","year":"2016","journal-title":"Endocr Dev"},{"issue":"6","key":"2024072411420702300_ref26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","article-title":"Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia","volume":"91","author":"Lorget","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2024072411420702300_ref27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/hmg\/ddr514","article-title":"A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model","volume":"21","author":"Jonquoy","year":"2012","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2024072411420702300_ref28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/toxsci\/kft161","article-title":"Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction","volume":"135","author":"Yanochko","year":"2013","journal-title":"Toxicol Sci"},{"issue":"3","key":"2024072411420702300_ref29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10637-017-0514-4","article-title":"Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors","volume":"36","author":"Nishina","year":"2018","journal-title":"Investig New Drugs"},{"issue":"4","key":"2024072411420702300_ref30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/dvdy.24479","article-title":"Achondroplasia: development, pathogenesis, and therapy","volume":"246","author":"Ornitz","year":"2017","journal-title":"Dev Dyn"},{"issue":"3","key":"2024072411420702300_ref31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"2024072411420702300_ref32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","article-title":"Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol"},{"issue":"203","key":"2024072411420702300_ref33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006247","article-title":"Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice","volume":"18","author":"Garcia","year":"2013","journal-title":"Sci Transl Med"},{"issue":"3","key":"2024072411420702300_ref34","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.bbrc.2018.07.044","article-title":"The FGF2 aptamer inhibits the growth of FGF2-FGFR pathway driven lung cancer cells","volume":"503","author":"Hamamoto","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"2024072411420702300_ref35","volume-title":"Pfizer to Discontinue the Development of Recifercept for Achondroplasia","author":"BeyondAchondroplasia.org","year":"2023"},{"key":"2024072411420702300_ref36","volume-title":"VOXZOGO Summary of Product Characteristics","author":"EMEA","year":"2021"},{"key":"2024072411420702300_ref37","volume-title":"VOXZOGO Highlights of Prescribing Information","author":"Food and Drugs Administration","year":"2021"},{"issue":"Supplement_1","key":"2024072411420702300_ref38","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad114.1525","article-title":"OR27-03 oral Infigratinib treatment is well tolerated and significantly increases height velocity in children with achondroplasia: month 6 results from the PROPEL 2 dose-finding study","volume":"7","author":"Savarirayan","year":"2023","journal-title":"J Endocr Soc"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae051\/57348758\/zjae051.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/6\/765\/58622119\/zjae051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/6\/765\/58622119\/zjae051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T22:44:44Z","timestamp":1721861084000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/39\/6\/765\/7642560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,9]]},"published-print":{"date-parts":[[2024,7,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjae051","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,4,9]]}}}